Navigation Links
Novavax Reports First Quarter 2009 Financial Results
Date:5/8/2009

remaining outstanding convertible notes with common stock upon maturity, the Company believes it has sufficient funds to execute its current business plans for at least the next twelve months.

Conference Call

Novavax's management will host its quarterly conference call at 10:00 a.m. eastern time today. The live conference call will be accessible via Novavax's website at www.novavax.com under Investor/Events or by telephone at 1 (866) 225 4091 (U.S. or Canada) or 1-703-639-1128 (International). An archive of the conference call will be available on Novavax's website approximately one hour after the event for 90 days. A replay of the webcast will be available on the website for 90 days after the call and a replay of the conference call will also be available by telephone beginning May 8, 2009 at 1:00 pm through May 13, 2009 at 11:59 pm. To access the replay, dial 1 (888) 266 2081 and enter passcode 1357908.

About Novavax

Novavax, Inc. is a clinical-stage biotechnology company creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like-particle (VLP) technology. The company produces these VLP-based, potent, recombinant vaccines utilizing new and efficient manufacturing approaches. Additional information about Novavax is available at www.novavax.com and in the company's various filings with the Securities and Exchange Commission. Additional information about Novavax is available at www.novavax.com and in the company's various filings with the Securities and Exchange Commission.

Forward Looking Statements

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including
'/>"/>

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate
2. Novavax Announces Release Date of 2009 First Quarter, Financial Results and Investor Conference Call
3. Novavax Announces Early Retirement of $17 Million of Convertible Debt
4. NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains
5. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
6. Novavax Announces New Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
7. Novavax Announces Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
8. Novavax to Present at Cowen and Company 29th Annual Healthcare Conference
9. NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate Directed Against the Fusion (F) Protein
10. Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines
11. Novavax Announces Operational Status of Its Vaccine Pilot Plant and Commercial Launch Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 14, 2014 EquitiesIQ, a leading informational ... ALQA). Alliqua is an emerging biomedical company acquiring, developing, ... care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... seasoned management team and Board, which launched the company’s ...
(Date:1/14/2014)... In recent years, growing suspicion about ... product development and promotion has led to unprecedented levels ... by concerns about the insidious impact of commercialization of ... fines to the world’s biggest pharmas for illegal marketing ...
(Date:1/14/2014)... Bellingham, Washington, USA, and Cardiff, UK (PRWEB) January 13, ... and photonics technology development leader with more than 20 ... international society for optics and photonics . Hainsey will ... “We are delighted to have Dr. Hainsey join SPIE ...
(Date:1/14/2014)... BioMedomics, Inc. , a Point of ... and novel disease specific POC tests, announced today that it ... total of $690,000. The investment is from private investors and ... group of private investors has significant successful experience in early ...
Breaking Biology Technology:EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2BioMedomics, Inc. Closes $690K Round of Financing 2
... temper tantrums lately? Or an adolescent episode of hormone-clouded ... a bit of flagging memory? , ,Given that organizations ... another, it's easy to begin thinking about organizations as ... they age. It's even understandable to want a model ...
... ,Jia Hu of China - Source: Getty Images The ... every four years. They're held every year. Though this is ... year as the pervasive growth of the industry becomes part ... run every four years and last two weeks, the biotech ...
... MADISON, Wis. - Ownership and accountability is the way ... 448-bed community hospital in Madison that provides medical care ... living facility, laboratories and a home health care service. ... Methodist Hospital in 1987, Meriter includes more than 430 ...
Cached Biology Technology:Aging IT 2Aging IT 3The Olympics: A Biotech Perspective 2The Olympics: A Biotech Perspective 3Meriter IT team builds project performance through internal relationships 2Meriter IT team builds project performance through internal relationships 3Meriter IT team builds project performance through internal relationships 4
(Date:7/9/2014)... are less fit in terms of cardiorespiratory capacity, ... Moreover, southern adolescents are more obese and present ... those from the centre-north of Europe. , These ... ambitious study conducted by scientists from the University ... with 25 other European research groups. The study ...
(Date:7/9/2014)... if they are used in the right ways. ... Women,s Hospital and coauthors analyzed six use cases ... triage; decompensation (when a patient,s condition worsens); adverse ... multiple organ systems. They suspect that cost-savings benefits ... with all six scenarios will be significant. The ...
(Date:7/8/2014)... run" or as a well-deserved break, and you,ll eat less afterward. ... you,ll later eat more dessert and snacks to reward yourself. , ... involved two studies where adults were led on a 2 km ... going to be an exercise walk or a scenic walk. ... were then given lunch. Those who believed they had been ...
Breaking Biology News(10 mins):Adolescents from southern Europe are less fit and more obese than central-northern European peers 2The impact of big data on health care: Health Affairs' July issue 2
... today for the HudsonAlpha- Science 2014 Conference on ... HudsonAlpha biotechnology campus in Huntsville, Ala. The ... of this emerging scientific field. ImmunoGenomics sits at ... the use of DNA sequencing to improve disease diagnosis ...
... an oil spill, and images of fouled beaches and ... visible effects as well. For instance, even low levels ... fish embryos and larvae, reducing the likelihood that those ... for some time, but the underlying mechanism has remained ...
... by memory deficits. Basel scientists have now identified a ... is important for human brain activity, memory and the development ... online edition of the US journal Neuron . ... a telephone number - is a fundamental function of the ...
Cached Biology News:Registration opens for HudsonAlpha-Science's 2014 Conference on ImmunoGenomics 2Registration opens for HudsonAlpha-Science's 2014 Conference on ImmunoGenomics 3Scientists discover the mechanism of heart failure in fish exposed to oil spills 2Scientists discover the mechanism of heart failure in fish exposed to oil spills 3How memory and schizophrenia are connected 2
Full-length cDNA clone CS0DJ013YG01 of T cells (Jurkat cell line) of Homo sapiens (human). [Source:Uniprot/SPTREMBL;Acc:Q86SZ3] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
...
...
All-in-one mix, removes primers and dNTPs from PCR product for following direct sequencing...
Biology Products: